Surrozen, Inc. Form 8-K Summary
Business context and reporting period
Surrozen, Inc. filed this Current Report on Form 8-K on May 10, 2023, under Item 2.02 to announce financial results for the quarter ended March 31, 2023. The filing identifies Surrozen as a Delaware biotechnology company whose common stock and redeemable warrants trade on the Nasdaq Capital Market under the symbols SRZN and SRZNW, respectively.
Financial results and liquidity
The filing states that Surrozen issued a press release announcing its quarterly financial results and attached that release as Exhibit 99.1. The provided filing text does not include the underlying press release or clear values for revenue, net income or loss, operating expenses, cash flow, margins, debt, cash and cash equivalents, liquidity, or other financial metrics.
Material changes versus the prior comparable period
The provided text does not disclose specific period-over-period changes. Any comparison with the quarter ended March 31, 2022 would require review of the attached Exhibit 99.1 or the company’s related financial statements.
Guidance, outlook, risks, and unusual items
The filing text does not provide guidance, management commentary, clinical or business updates, risk disclosures, contingencies, or unusual items beyond the announcement of quarterly financial results. The filing also states that the Item 2.02 information, including the attached exhibit, is furnished and is not deemed filed for purposes of Section 18 of the Exchange Act.
Key facts for investors to verify
- Obtain and review Exhibit 99.1 for the actual March 31, 2023 financial results.
- Verify cash runway, operating cash burn, financing activity, debt obligations, and any going-concern disclosures.
- Compare revenue, net loss, research and development expense, general and administrative expense, and cash flow with the prior-year quarter.
- Review any management guidance, clinical-program updates, milestones, or financing plans included in the press release.
- Confirm the treatment of the press release as furnished rather than filed under Item 2.02.